c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 128 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DS-1205
CAS:<p>DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.</p>Fórmula:C41H42FN5O7Pureza:99.75%Cor e Forma:SolidPeso molecular:735.8PF-04217903
CAS:<p>MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule tyrosine kinase inhibitor with potential antineoplastic activity.</p>Fórmula:C19H16N8OPureza:98.41% - 98.55%Cor e Forma:SolidPeso molecular:372.38Savolitinib
CAS:<p>Savolitinib (Volitinib) (AZD-6094) is an effective, selective, and orally bioavailable c-Met inhibitor (IC50s: 5 nM/3 nM for c-Met/p-Met).</p>Fórmula:C17H15N9Pureza:98.12%Cor e Forma:SolidPeso molecular:345.36BMS-794833
CAS:<p>BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-817378.</p>Fórmula:C23H15ClF2N4O3Pureza:98% - 99.69%Cor e Forma:SolidPeso molecular:468.84Hepln-13
CAS:<p>Hepln-13 is a hepsin inhibitor that acts by hindering prostate cancer bone metastasis.</p>Fórmula:C17H13BrN2Pureza:97.67%Cor e Forma:SolidPeso molecular:325.2XL092
CAS:<p>XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.</p>Fórmula:C29H25FN4O5Pureza:98.60%Cor e Forma:SolidPeso molecular:528.53NPS-1034
CAS:<p>NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively.</p>Fórmula:C31H23F2N5O3Pureza:98.48%Cor e Forma:SolidPeso molecular:551.54Merestinib dihydrochloride
CAS:<p>Merestinib dihydrochloride (LY2801653 dihydrochloride) is a kinase inhibitor with antitumor activity that inhibits MET and MKNK1/2.</p>Fórmula:C30H24Cl2F2N6O3Cor e Forma:SolidPeso molecular:625.45AMG-337
CAS:<p>AMG-337 is an effective and highly specific ATP-competitive MET kinase inhibitor. In enzymatic assays, AMG-337 inhibits MET kinase activity (IC50: < 5 nM).</p>Fórmula:C23H22FN7O3Pureza:99.26% - 99.9%Cor e Forma:SolidPeso molecular:463.46Afatinib Dimaleate
CAS:<p>Afatinib Dimaleate (BIBW 2992MA2) is an orally bioavailable anilino-quinazoline derivative and inhibitor of the EGFR family, with antineoplastic activity.</p>Fórmula:C32H33ClFN5O11Pureza:98.11% - 99.87%Cor e Forma:SolidPeso molecular:718.08SCR-1481B1
CAS:<p>SCR-1481B1 (c-Met inhibitor 2) has activity against cancers dependent on Met activation and also has activity against cancers as a VEGFR inhibitor</p>Fórmula:C32H40ClF2N6O13PPureza:98.07%Cor e Forma:SolidPeso molecular:821.12X-376
CAS:<p>X-376 (Ensartinib) is an orally available small molecule inhibitor of the receptor tyrosine kinase ALK with potential antineoplastic activity.</p>Fórmula:C25H25Cl2FN6O3Pureza:97.87%Cor e Forma:SolidPeso molecular:547.41Golvatinib
CAS:<p>Golvatinib (E-7050) is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor</p>Fórmula:C33H37F2N7O4Pureza:98.24% - ≥95%Cor e Forma:SolidPeso molecular:633.69c-Kit-IN-1
CAS:<p>c-Kit-IN-1 (DCC-2618) is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).</p>Fórmula:C26H21F2N5O3Pureza:98.72% - 98.73%Cor e Forma:SolidPeso molecular:489.47Tivantinib
CAS:<p>Tivantinib (ARQ 197) is an orally bioavailable small molecule inhibitor of c-Met with potential antineoplastic activity.</p>Fórmula:C23H19N3O2Pureza:98% - 99.41%Cor e Forma:SolidPeso molecular:369.42Altiratinib
CAS:<p>Altiratinib (DCC-2701)(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling,</p>Fórmula:C26H21F3N4O4Pureza:99.67% - 99.75%Cor e Forma:SolidPeso molecular:510.46Ningetinib
CAS:<p>Ningetinib (CT-053) (CT053PTSA) is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Fórmula:C31H29FN4O5Pureza:99.95% - 99.98%Cor e Forma:SolidPeso molecular:556.58Ningetinib Tosylate
CAS:<p>Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.</p>Fórmula:C38H37FN4O8SPureza:99.93%Cor e Forma:SolidPeso molecular:728.79NVP-BVU972
CAS:<p>NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.</p>Fórmula:C20H16N6Pureza:97.24% - >99.99%Cor e Forma:SolidPeso molecular:340.38Capmatinib xHCl
CAS:<p>Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50</p>Fórmula:C23H18ClFN6OPureza:98.62% - 99.81%Cor e Forma:SolidPeso molecular:448.89
